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Abstract  
Objective 
To clinically and pathologically characterize a cohort of patients presenting with a novel form of 
distal myopathy and to identify the genetic cause of this new muscular dystrophy.  
Methods 
We studied four families (three from Spain and one from Sweden) suffering from an autosomal 
dominant distal myopathy. Affected members showed adult-onset asymmetric distal muscle 
weakness with initial involvement of ankle dorsiflexion later progressing also to proximal limb 
muscles. 
Results 
In all three Spanish families, we identified a unique missense variant in the ACTN2 gene co-
segregating with the disease. The affected members of the Swedish family carry a different ACTN2 
missense variant. 
Interpretation 
ACTN2 encodes for alpha actinin2 that is highly expressed in the sarcomeric Z-disk with a major 
structural and functional role. Actininopathy is thus a new genetically determined distal myopathy. 
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Introduction 
Distal myopathies, also called distal muscular dystrophies, are rare genetic diseases1, 2, 
characterized by predominant weakness in the feet and/or hands, due to dystrophic degeneration of 
distal muscles in the lower, and less frequently, upper extremities1, 2. Although more than 20 
different genes have been identified so far, a large number of patients do not harbor mutations in 
previously known disease genes3. 
Here we report four families with distal myopathy, sharing a similar clinical phenotype and a 
common pattern of muscle involvement. In all these families enrolled in the study, we identified 
missense variants in the alpha-actinin-2 gene (ACTN2, located on chromosome 1q43)4 co-
segregating with the disease. 
ACTN2 mutations have previously been associated with both hypertrophic and dilated 
cardiomyopathies (HCM and DCM)5, 6, but not with skeletal myopathies. Actinins are expressed in 
all human cells, they form dimeric filament cross-linking proteins7. Mammals have four genes 
encoding for slightly different proteins7. Alpha-actinin-2, in particular, is highly abundant in cardiac 
and skeletal muscle where it plays several functional and structural roles in the sarcomeres7. It is 
located in the Z-disk where it cross-links actin and titin filaments acting as a scaffold for other Z-
disk proteins and also as a mechanosensor serving various signaling functions7-9.  
Despite the crucial role of alpha-actinin-2 and its interactions with other clinically relevant 
sarcomeric proteins7, 9, 10, no ACTN2 disease-causing mutations have been identified in patients with 
familial myopathies. During the preparation of our work we were aware of two sporadic patients 
with a different congenital progressive core myopathy being studied for ACTN211. 
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Materials and methods 
Study subjects and clinical examinations 
Four families with 18 patients affected by a distal myopathy of unknown genetic causes were 
investigated. Three families were from northern Spain (Families 1-3) and family 4 was from 
Sweden. 
All the families showed an autosomal dominant inheritance pattern (Fig 1).  
The patients had been clinically examined and most of them followed up over many years (Families 
1, 2, and 4 for 8-15 years; family 3 for one year). Muscle imaging data, electrophysiological 
examination results (nerve conduction studies and needle electromyogram, EMG), creatine kinase 
(CK) measurements and cardiac function test results were obtained in most patients (Table 1).  
All the patients provided written informed consent. The study was approved by Ethics Review 
Board of Helsinki University Hospital (number 195/13/03/00/11) and performed according to the 
Declaration of Helsinki. 
 
Muscle biopsy 
Muscle biopsies were obtained from five individuals and processed using standard histochemical reactions. 
Immunohistochemical analysis was performed using desmin (DakoCytomation, CloneD33) and myotilin 
(Novocastra, Clone RSO34) monoclonal antibodies. Moreover immunofluorescent (IF) stainings were 
performed using the following primary antibodies: monoclonal anti-alpha-actinin ACTN2/3 
antibody (Sigma-Aldrich, clone EA-53); polyclonal anti-myotilin (ProteinTech 10731-1-AP); 
polyclonal anti–p62 (Millipore/Sigma P0067); and monoclonal anti-TDP-43 (Sigma-Aldrich 
WH0023435M1-1). Alexa-488 and Alexa-546 Fluor–conjugated secondary antibodies were used 
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for detection, and Hoechst nuclear counterstain was performed prior to mounting in Fluoromount 
(Thermo Fisher Scientific). 
A small sample of biopsies was fixed in 2% glutaraldehyde, postfixed with 1% osmium tetroxide, 
and embedded in araldite. Ultrathin sections were stained with uranyl acetate and lead citrate and 
viewed with a JEOL 1011 electron microscope.  
 
Genetics 
Genomic DNA was isolated from blood cells using standard techniques. DNA samples from the 
probands of Families 1,2 and 4 were sequenced using MYOcap, a targeted high-throughput 
sequencing panel12. Raw NGS data was analyzed by an in-house pipeline12. Experimental validation 
of ACTN2 variants and segregation analysis were performed by PCR (primers available on request) 
and Sanger sequencing. ACTN2 variants are described on transcript NM_001103. 
A SNP genotyping (Illumina Infinium) was performed using the available DNAs from family 1 
(III,1;III,4;III,6;IV,3;IV,4;IV,5;IV,6;IV,7;IV,8;IV,9;IV,10), family 2 
(II,1;II,3;II,4;II,6;II,7;III,1;III,2) and family 3 (II,1). 
A whole exome sequencing using SeqCap EZ MedExome (Roche, Basel, Switzerland) was 
performed on probands of family 1 (IV,2) and 3 (II,1) at the Finnish Institute of Molecular 
Medicine (FIMM) with Illumina HiSeq2500 system. Reads were aligned to the human reference 
genome (GRCh38/hg38) with the BWA13, and a GATK standard pipeline was used for variant 
calling. Variants were then annotated using Annovar14. 
RNA from patient II,7 in family 2 was extracting with the RNeasy Plus Universal mini kit 
(QIAGEN, Hilden, Germany) according to the manufacturer's protocol. cDNA synthesis was 
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performed with High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Ghent, 
Belgium). RT-PCR was performed using primers designed with Primer3 software (available on 
request) and a Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific, Madison, 
Wisconsin, USA). 
 
Structure modelling 
Human alpha-actinin2 was visualized in DeepView/Swiss-PdbViewer v 4.1.0 15 and POV-Ray v. 
3.7 (http://www.povray.org) using the structures 5A3616 and 4D1E9 from PDB. 
 
  
This article is protected by copyright. All rights reserved.
Results 
Clinical features 
Family 1 
Nine patients in two generations were clinically investigated. In addition three family members 
(II:1, II:2, III:4) were considered affected as they had similar distal weakness and walking 
difficulties, but were already deceased and not available for further studies (Fig 1). The mean age at 
symptom onset was 40.5 years (range 34-53 years). The presenting symptom was distal lower leg 
weakness especially with bilateral or one-sided foot drop in five of the patients. Two patients 
presented with myalgia while two patients were subjectively asymptomatic. Muscle weakness was 
predominant in the anterior compartment of the leg but, as the disease slowly progressed, the 
symptoms encompassed also posterior lower leg and proximal lower limb muscles. In the beginning 
of the disease, calf muscles and quadriceps could be asymmetrically hypertrophic and later became 
atrophic. Upper limb, trunk or facial muscles were not affected. EMG in the leg muscles mainly 
showed myopathic polyphasic brief and low amplitude potentials and early recruitment with some 
fibrillation and polyphasic larger amplitude potentials. One patient had ischemic heart disease and 
pacemaker; otherwise, none had cardiac or respiratory symptoms. One patient underwent Holter-
ECG and echocardiography examination with normal results. CK values were variable ranging from 
normal to markedly elevated, up to 5000 UI/L. One patient presented as asymptomatic hyperckemia 
(1000-3000 U/L).  The clinical details of the patients are shown in Table 1. 
 
Family 2 
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The patients of family 2 presented with lower limb weakness between the ages of 41-63 years. In 
addition to distal lower leg weakness, the oldest patients of the family had severe proximal lower 
limb weakness. Two patients had asymmetrical involvement in the distal upper limbs (Table 1). 
Two patients were asymptomatic but on clinical examination were found to have hypertrophic 
quadriceps muscles and slightly elevated CK levels (233-249 IU/L, normal range 0-189 IU/L). One 
of the two was also unable to walk on heels. The other patients had clearly elevated CK levels (400-
1770 IU/L). EMG showed polyphasic, brief, low amplitude potentials with early recruitment in the 
leg muscles. Echocardiogram and Holter-ECG were normal in three patients studied. 
 
Family 3 
The father and son were the only affected members of family 3. The father had gait difficulties 
since the age of 60 years and on examination, he had asymmetric bilateral ankle dorsiflexion 
weakness with steppage gait. He also had proximal lower limb weakness causing difficulties rising 
from a chair. His son noticed muscle atrophy in both forearms more evident on the right at age 38. 
Wrist extensor weakness developed later. In addition, he had left ankle dorsiflexion weakness he 
had not been aware of. Both had the same mixed pattern on EMG as Family 1, and elevated CK 
levels (330-994 IU/L). Holter-ECG and echocardiogram of the son were normal. The father has 
been diagnosed of atrial flutter at the age of 73 years. Echocardiogram showed left ventricular 
hypertrophy. 
 
Family 4 
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The father had distal lower limb weakness starting at age 45. Muscle weakness progressed to 
proximal lower limb muscles causing waddling and steppage gait. The daughter had a combination 
of proximal and distal lower limb weakness since aged 45 years. In addition, she had abdominal and 
neck flexor weakness. The father lost ambulation while the daughter uses two sticks for ambulation 
at the age of 62 years. 
 
Muscle imaging 
Muscle MRI or CT data were available in 15 patients. Imaging findings in each patient are listed in 
Table 1. The mildest cases showed fatty degenerative changes only in tibialis anterior muscles. In 
addition, frequently affected muscles were extensor digitorum longus, soleus and gastrocnemius 
medialis (Fig. 2). With more advanced disease, fatty degeneration was severe in most thigh and 
usually also gluteal muscles. The observed pattern of involvement was similar between families 
with less severe findings in rectus femoris, gracilis, sartorius and semitendinosus (Fig. 2). Muscle 
imaging findings were asymmetric in most of the patients. 
Muscle pathology 
Muscle biopsy features varied from one case to another probably depending on the stage of the 
disease (Fig. 3). In the most severe cases there was prominent variation in the fiber size, increased 
numbers of internal nuclei and fibro-fatty tissue proliferation. Large numbers of fibers contained 
rimmed vacuoles. Moreover, some inclusion bodies were eosinophilic on HE stain and displayed 
congophilia. On oxidative reactions, there were major architectural changes with areas of 
myofibrillar disorganization and abundant lobulated fibers (Fig 3. A to E). ATPase reaction 
revealed type I predominance, and some myopathic type- grouping. No major protein aggregates 
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were observed by using antibodies against desmin and myotilin except for very well defined 
inclusion bodies displaying p62 immunoreactivity and non-specific, diffuse desmin 
immunoreactivity in the atrophic fibers (data not shown). Immunofluorescence analysis revealed 
alpha-actinin enhancement in small atrophic fibers, and very occasional fibers containing small p62 
and TDP-43 positive aggregates (Fig. 4). 
Examination of a biopsy from a less affected individual revealed centrally located areas rounded or 
oval, that were hardly seen on HE stain, but were easily identified with PAS staining, and with 
oxidative reactions. These lesions displayed less intense oxidative activity than the surrounding area 
but were not devoid of oxidative activity, and therefore were not cores (Fig. 3 F to I).  
Ultrastructural examination (Fig. 5) revealed severe myofibrillar abnormalities, with loss of normal 
striation pattern and thickening, duplication and fragmentation of the Z-lines. The majority of 
atrophic fibers showed a complete disorganization of the sarcomere structure that was replaced by 
remnants of filaments and fragments of Z-lines. There were autophagic vacuoles, and occasional 
cytoplasmic inclusions of 18 nm tubulofilaments. Additional utrastructural findings were electron-
dense inclusions surrounded by a clear halo resembling cytoplasmic bodies, core-like lesions, small 
areas of Z-line streaming, inclusions of electron-dense material of Z-disc origin and occasional 
honeycomb structures. Aberrant orientation of the myofibrils was the major abnormal finding in the 
sample showing the central lesions described above (Fig. 5 I). 
 
  
Molecular genetics 
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We identified an ACTN2 c.1459T>C (p.C487R) variant (Fig 1) in all the probands in families 1–3. 
In family 4, an ACTN2 c.392T>C (p.L131P) variant was identified. These missense variants are 
both private (not listed in gnomAD17 or in any other public database). Sanger sequencing, 
performed on the relatives for whom DNA was available, confirmed the co-segregation of the 
identified variants with the disease.  
In family 4, the proband (II, 1) carried a truncating variant in titin gene (TTN; 
NM_133379:c.14454del:p.Ala4819Leufs*10) along with two further rare TTN missense variants. 
None of these TTN variants were identified in her affected father. 
A linkage analysis in families 1, 2 and 3 showed a 1.8 Mb-long region (between rs34121575 at 
genomic position 2: 235181733 and rs6668721 at 2: 237127704) spanning ACTN2. WES analysis 
confirmed that the only rare (MAF<1% in gnomAD) exonic nonsynonymous variant shared by 
patient IV,2 in family 1 and patient II,1 in family 3 within the linked region was the ACTN2 
c.1459T>C (p.C487R) variant. Finally, a cDNA analysis demonstrated that the variant did not affect 
the splicing.  
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Discussion 
Autosomal dominant distal myopathies with lower leg preponderance and rimmed vacuolar 
pathology with sarcomeric abnormalities are all within the differential diagnostic scope of this 
actininopathy. Clinically, this entity is characterized by adult-onset asymmetric weakness and 
atrophy of tibialis anterior muscle, slowly progressing to proximal muscles. In the first stages of the 
disease CK can be very high and calf or quadriceps hypertrophy present. Although ACTN2 
mutations have been associated with cardiomyopathy, our patients did not present cardiac 
involvement.  
Alpha-actinin-2 is a protein highly expressed in the Z-disk of cardiac and skeletal sarcomeres, 
where it plays several structural and functional roles7, 9, 10. It connects the anti-parallel actin 
filaments to the sarcomeres and is an anchor for other Z-disk proteins. Through a number of 
interactions it is involved in signaling and mechanosensation7-9, 18, 19.  
Alpha-actinin-2 has a modular structure with an N-terminal actin-binding domain (ABD) containing 
2 calponin homology domains (CH1 and CH2), a central rod domain with four spectrin-like repeats 
(SRs), and a C-terminal calmodulin-like domain (CAMD) composed of two hand motifs (EFs)4, 9. 
In a closed conformation, alpha-actinin-2 is an antiparallel homodimer, stabilized by interactions 
between the SRs9.  
In striated muscles, CAMD binds a specific hydrophobic alpha-actinin-binding motif located in titin 
z-repeats8, 18. The alpha-actinin interaction with titin and actin is highly dynamic and likely 
regulated by phospholipids as well as by complex intramolecular mechanisms8, 9, 18. The stable 
anchoring of the sarcomeric backbone titin within the Z-disk is provided by its interaction with 
alpha-actinin18.  
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Interestingly, alpha-actinin-2 interacts with at least three other proteins involved in a distal 
myopathy: the aforementioned titin8, 18, the UDP-N-acetylglucosamine 2-epimerase (GNE)20, and 
the Z-disc-associated, Alternatively Spliced, PDZ Motif-containing Protein (ZASP)21.   
Considering the peculiar role of alpha-actinin-2 in skeletal muscle and its interactions with other 
clinically relevant proteins, ACTN2 has been considered for a long time a strong candidate gene for 
skeletal muscle disorders. Nevertheless, ACTN2 mutations have been linked for long time only to 
various cardiomyopathies such as HCM, DCM and other cardiac phenotypes5, 6. Two sporadic 
patients with a congenital core myopathy studied at the same time with our families and carrying 
two ACTN2 variants in the fourth spectrin repeat have been just published11. 
In this study, we have described mutations in the ACTN2 gene causing a late onset distal myopathy. 
In all the families enrolled, the private ACTN2 variants are fully penetrant and perfectly co-
segregate with the disease. Both variants are predicted to be causative by most of the bioinformatic 
programs currently in use (e.g. Polyphen22 and Mutation Tester23). In particular, Cysteine 487 is a 
conserved amino acid located in the second spectrin repeat. The spectrin repeats are important for 
dimerization. In silico structural studies suggest that a mutation of this partially buried cysteine to 
the much larger, positively charged arginine could reduce the stability of this repeat and might 
indirectly interfere with dimerization (Fig 6). 
Leucine 131 is in an α-helix in the first Calponin Homology (CH1) in the ABD domain. A mutation 
to proline will induce a kink in the helix and cause loss of the backbone H-bond to tryptophan 135. 
The interaction of tryptophan 135 with arginine 243 holds CH1 and CH2 together. The variant 
p.L131P probably destabilizes the structure, hampering a correct folding of the protein (Fig 6), 
which will need further studies. 
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Moreover, all our patients carrying ACTN2 mutations share a very similar clinical phenotype, a 
characteristic pattern of muscle involvement by MRI and common histologic features. 
The co-occurrence of the p.C487R variant in three families coming from the same village in 
northern Spain suggests that the three families may have a common ancestor through a founder, 
although no familial relationship is known. Most likely this ACTN2 founder mutation will be 
identified in more patients from northern Spain with an adult-onset distal myopathy. 
Our data demonstrates that ACTN2 mutations cause a new type of dominant late-onset and slowly 
progressive distal myopathy. The wide spectrum of ACTN2-related clinical phenotypes probably 
reflects the observed high genetic heterogeneity and the complex network of interactions ACTN2 
has with other sarcomeric proteins. The identification of additional patients with an ACTN2-related 
myopathy will probably improve the understanding of the genotype-phenotype correlation. 
Similarly, additional functional studies are needed to clarify and understand the molecular 
mechanisms of the disease leading to dystrophic loss of muscle tissue in the particular target 
muscles. 
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Figure 1: Pedigrees of the families enrolled in this study 
DNA was collected from individuals marked with an asterisk *.  
Figure 2: Muscle MRI 
Milder form of involvement in patient F1 IV:3 shows affected tibialis anterior, extensor digitorum 
longus and gastrocnemius medialis muscles on the left. More advanced fatty degenerative changes 
are seen in patients F4 II:1 and F3 I:1 with large amount of thigh and leg muscles affected. 
Relatively spared muscles are rectus femoris, gracilis, sartorius and semitendinosus. At the distal 
leg tibialis anterior, soleus and gastrocnemius medialis are most frequently degenerated.  
Figure 3: Histological findings 
Muscle biopsy from patient F1 IV: 2 (A to E), showing variation in the fiber size, increased 
numbers of internal nuclei and fibro-fatty tissue proliferation (A), and rimmed vacuoles (A, B and 
D). Some fibers contain inclusion bodies eosinophilic on HE (B), and dark green (C) and displaying 
congophilia (D). NADH reaction showing lobulated fibers (E) Muscle biopsy from individual F1 
IV: 7 (F to I) revealing variation in the fiber size, increased numbers of internal nuclei mild 
endomysial fibrosis. Note the presence of centrally located areas hardly seen on HE stain (F), but 
clearly revealed with PAS staining (G), and with oxidative reations (H). ATPase shows type I 
predominance, and some myopathic type- grouping (I). 
Figure 4: Alpha-actinin immunolabeling  
Patient F1 IV:2 Myotilin (green), alpha-actinin ACTN2/3 (red): alpha-actinin immunolabeling is 
enhanced in small atrophic fibers in the patient biopsy. p62 (green), TDP-43 (red): some fibers 
show small p62 and TDP-43 positive aggregates. 
Figure 5: Ultrastructural features in actininopathy  
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(A) Focal disruption of sarcomere structure with streaming of Z-line spanning one sarcomere and 
emanation of electron-dense material. (B) Large area of sarcomeric disorganization and 
accumulation of dark material probably of Z-disk origin. (C to E) Severe loss of sarcomere structure 
with large areas or the totality of the muscle fiber replaced by fragmented sarcomeres, and 
fragments of thickened Z-lines. (F) Electron-dense inclusions surrounded by a clear halo resembling 
cytoplasmic bodies. (G) Collections of 18 nm tubulofilaments (inset) within the cytoplasm of a 
muscle fiber. (H) Autophagic material and cellular debris. (I) Transversal section showing aberrant 
orientation of the myofibrils. 
Figure 6: Positions of ACTN2 mutations 
(A) The structure of the ABD domain of human ACTN2 (5a36.pdb) showing the location of 
Leu131 together with the residues important for CH1-CH2 binding (Trp135 and Arg243). Leu131 
is interacting with residues in helix1 of CH1. 
(B) Structure of the second spectrin domain of human ACTN2 (4d1e.pdb) showing the location of 
Cys487 and residues within 5 Å from the Cys487 side chain. Cys487 is in close proximity with 
residues in other alpha-helices in this domain 
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Table 1 – Clinical details 
Patient Age at 
last 
exam/ 
sex 
First symptoms/ age at 
onset 
Muscle findings (MRC) Muscle imaging CK* UI/L 
F1 III:1 
 
77/F Foot drop/ n.a. Distal LL weakness and atrophy, posterior and 
anterior compartment, steppage gait on the left, 
right calf hypertrophy, ambulant with a walker 
n.a. 382 
F1 III:2 
 
63/F Left foot drop/ 53y Ankle dorsifl L>R, mild gluteal weakness, 
absent tendon reflexes 
Hamstrings (R>L), TA, EDL, 
Gmed, S 
319 
F1 III:3 
 
57/F Foot drop/ 37y Ankle dorsifl (0/5, 1/5), right gastrocnemius  Hamstrings, VI, anterolateral and 
posterior lower leg (R>L) 
531 
F1 IV:2 
 
37/M Right calf pain/ 34y Unable to walk on toes or heels, right side S, Gmed, Glat, mild TA, mild 
hamstrings  
5000 
F1 IV:3 
 
42/F Unable to walk on 
toes/heels (left)/ n.a. 
Distal atrophy on the left posterior and anterior 
compartment 
TA (L), EDL (L), Gmed (L) 1648 
F1 IV:4 
 
34/F Asymptomatic Hypertrophic muscles, no weakness TA (L>R) 485 
F1 IV:5  43/F Clumsy right foot/ 38y Distal anterior compartment atrophy L>R, 
ankle dorsifl (3/5), peroneal (4/5, 3/5) calf 
hypertrophy, bilateral Achilles’ tendon 
areflexia 
n.a. 172 
F1 IV:7 
 
36/M Asymptomatic Calf hypertrophy S (R>L), mild TA (R), anterior 
thigh (L>R) 
1000-
3000 
F1 IV:10 47/F Myalgia/ n.a. 
 
No findings Normal 147 
F2 I:1 
 
81/M Lower limb weakness/ 
63y 
Hip extension (1/5), thigh abductors (2/5), thigh 
adductors (1/5), quadriceps (3-4/5, L>R), 
ischiotibial (2/5), ankle dorsifl and plantar fl 
(4/5) 
Adductors, hamstrings, S, pectoral 
and paraspinal muscles 
400-
normal 
F2 II:3  55/M Right quadriceps atrophy/ 
45y 
Gluteal muscles, thigh adductors (2/5), 
hamstrings (4/5), ankle dorsifl (4/5, 3/5), left 
peroneal (3/5), left finger ext (4/5). Ambulant 
with waddling and steppage gait, hyperlordosis 
Adductors, hamstrings, vastus 
intermedius, anterolateral lower leg, 
S 
1646 - 
897 
F2 II:4 
 
53/F Asymptomatic Quadriceps hypertrophy, ankle dorsifl (4/5), 
unable to walk on heels 
TA 249 
F2 II:5  46/M Difficulties climbing 
stairs/ 41y 
Right carpal radial extensors atrophy, anterior 
external compartment atrophy, calf 
hypertrophy, difficulties walking on toes 
Gluteal, adductors (L), hamstrings, 
vastus intermedius, TA, S 
1771 - 
1407 
F2 III:3  21/F Asymptomatic 
 
Quadriceps hypertrophy Normal 233 
F3 I:1  
 
70/M Gait difficulties/ 60y Asymmetric bilateral weakness of tibialis 
anterior with steppage gait. 
Some difficulties to get up from a chair. 
Atrophy of anterior compartment of left leg 
Gluteal and thigh muscles, S, TA, 
Gmed, peroneal 
330 
F3 II:1 
 
43/M Atrophy of extensor carpi 
radialis/ 38y 
Wrist ext, left ankle dorsifl TA (L), Gmed/lat (R) 994 
F4 II:1 
 
80/M Distal lower leg 
weakness/ 45y 
Foot drop, severe proximal LL (L>R), WCB Gluteal, anterior thigh and 
hamstring muscles, anterolateral leg 
muscles (L>R), S, mild Gmed 
Normal 
F4 III:1  62/F Right ankle dorsifl and 
proximal weakness/ 45y 
Ankle dorsifl (R>L), proximal LL (hip/ knee 
ext), waddling gait, neck fl and abdominal. 
Ambulant with two sticks 
n.a. n.a. 
 
BF, biceps femoris; CK, creatine kinase; EDL, extensor digitorum longus; F, female; Gmed, gastrocnemius medialis; Glat, 
gastrocnemius lateralis; L, left; LL, lower limbs; M, male; MRC, The Medical Research Council scale; n.a., not available, R, right; S, 
soleus; SM, semimembranosus; TA, tibialis anterior; UL, upper limbs; VI, vastus intermedius; WCB, wheelchair bound 
*normal values for CK are 0-189 IU/L 
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